Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2006-09-01

FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for Zarontin (ethosuximide) submitted by Parke-Davis Div of Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZARONTIN (ethosuximide)

Snippet

SUPPL AP for ZARONTIN (ETHOSUXIMIDE)